Business Context and Reporting Period
This Form 8-K Current Report was filed by Organogenesis Holdings Inc. on May 24, 2021. The filing addresses corporate governance changes and a resulting compliance issue with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
- Board Resignation: Joshua Tamaroff resigned from the Board of Directors and all committees effective May 24, 2021.
- Reason for Resignation: The resignation was not due to any disagreement with the Company regarding operations, policies, or practices. It coincided with Avista Capital Partners distributing its remaining shares of the Company's Class A common stock to partners on May 26, 2021.
- Listing Non-Compliance: The resignation caused the Company to fall out of compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee to consist of at least three independent directors.
Outlook, Risks, and Management Commentary
- Cure Period: The Company has been granted a cure period to regain compliance with the Audit Committee composition requirement. This period expires on the earlier of the next annual stockholders' meeting or May 24, 2022.
- Compliance Deadline: If the next annual stockholders' meeting is held on or before November 20, 2021, the Company must comply by that date.
- Management Expectation: The Company expects to regain compliance with the Nasdaq listing rules by or before the end of the cure period.
Investor Verification Checklist
- Verify the current composition of the Audit Committee to ensure it meets the three independent director requirement.
- Confirm the date of the next annual stockholders' meeting to determine the specific compliance deadline.
- Review the Schedule 13D/A filed on May 27, 2021, for details on the Avista Capital Partners share distribution.
- Monitor future filings for the appointment of a new independent director to restore full compliance.